HopeStage
Back to all studies
CompletedNCT01041274

Citalopram added to treatment for depression in first-episode schizophrenia

About this titleRead the official source — NCT01041274
Medication studyAges 16–40United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 16 years to 40 years.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: January 2010
Recruitment status
Completed
Enrollment listed in the registry
95
Sponsor
NYU Langone Health
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Behavioural, Drug, Radiation
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 16 Years to 40 Years
Official registry ID
NCT01041274
Official title
Show the full official title

Citalopram in First Episode Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New York

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is NYU Langone Health.

Did this study involve medication?

Yes. The study involved medication, including Citalopram and Placebo.

Who was this study for?

Listed age limits: 16 years to 40 years.

Want to explore more studies?

Explore studies